Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Eitemau Tebyg

• A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer
  gan: Gatti‐Mays, Margaret E., et al.
  Cyhoeddwyd: (2020)
• Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
  gan: Brill, Ethan, et al.
  Cyhoeddwyd: (2017)
• Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
  gan: Nair, Jayakumar, et al.
  Cyhoeddwyd: (2020)
• Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
  gan: Lee, Jung-Min, et al.
  Cyhoeddwyd: (2018)
• Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8(+) T cells compared with women with BRCA wild-type disease during the early disease course
  gan: Lee, Jung-Min, et al.
  Cyhoeddwyd: (2019)